Disclose additional Phase 2 development programs
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 18 May 2023
- Due
- 31 Dec 2023
- Checked
- 4 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Any additional Phase 2 development programs not already announced which are driven by data from the full Phase 1 data and other opportunistic considerations are expected to be disclosed by year end.”
What we found
Evidence strength A What the grades mean
Replimune revised its commitment timeline from year-end 2023 to early 2024, then to 2025, missing the original deadline.
-
A Replimune Group, Inc. - Form 10-K - FY2023
“Any additional Phase 2 development programs not already announced which are driven by data from the full Phase 1 data and other opportunistic considerations are expected to be disclosed by year-end 2023.” ✓ confirmed on the page
-
A Replimune Group, Inc. - Form 10-Q - FY2023
“Any additional Phase 2 development programs not already announced which are driven by data from the full Phase 1 data and other opportunistic considerations are expected to be announced in early 2024.” ✓ confirmed on the page
-
B Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
“Replimune Group, Inc. (NASDAQ: REPL) today announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naïve metastatic uveal melanoma and second-line recurrent or metastatic hepatocellular carcinoma”
Checked 4 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Disclose
- Deliverable
- Additional Phase 2 development programs
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002712 · Corrections policy